Vixarelimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | KPL-716; BIIB069; BIIB-069 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Vixarelimab (KPL-716) is a fully human monoclonal antibody that works by binding to the oncostatin M receptor β, thus inhibiting both interleukin 31 and oncostatin M. It is developed by Kiniksa Pharmaceuticals for prurigo nodularis.[1][2][3]
References
[edit]- ^ "Vixarelimab". go.drugbank.com. Retrieved 19 November 2023.
- ^ Sofen, Howard; Bissonnette, Robert; Yosipovitch, Gil; Silverberg, Jonathan I.; Tyring, Stephen; Loo, Wei Jing; Zook, Matthew; Lee, Mark; Zou, Liangxing; Jiang, Guang-Liang; Paolini, John F. (March 2023). "Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study". eClinicalMedicine. 57: 101826. doi:10.1016/j.eclinm.2023.101826. PMC 9932343. PMID 36816342.
- ^ Richards, C; Gandhi, R; Botelho, F; Ho, L; Paolini, J (2020). "Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716". Acta Dermato Venereologica. 100 (14): adv00197. doi:10.2340/00015555-3505. PMC 9199921. PMID 32374409.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |